Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Regulatory News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

Cancellation of Listing

9 Sep 2009 16:26

RNS Number : 7983Y
Celsis International PLC
09 September 2009
Β 

ο»Ώ

CELSIS INTERNATIONAL PLC

("Celsis", "the Company" or "the Group")

Notice ofΒ application ofΒ cancellation of Listing

9 September 2009:Β Celsis International plc, the life sciences products and laboratory services company, today announces that following the announcement earlier today that Nastor Investments Limited ("Nastor Investments") either owned or had received valid acceptances in respect of, in aggregate, 16,513,640 Celsis Shares, carrying approximately 75.4 per cent. of voting rights attached to the existing issued share capital of CelsisΒ and that as a result, Nastor Investments would now procure the making of an application by Celsis for the cancellation of the listing of Celsis Shares on the Official List and the admission to trading of Celsis Shares on the London Stock Exchange,Β CelsisΒ has made an applicationΒ for the cancellation of the listing of Celsis Shares on the Official List and the admission to trading of Celsis Shares on the London Stock Exchange.Β 

It is anticipated that cancellation of the Celsis listing and admission to trading will take effect on 8 October 2009, beingΒ the required notice period, such notice period having now commenced,Β of not less thanΒ 20 business days following the date of this announcement.

General

Terms used in this announcement shall have the meaning given to them in the Offer Document dated 10 August 2009, unless the context requires otherwise.Β 

In accordance with Rule 19.11 of the City Code, a copy of this announcement will be published on the following websites: www.navalue.co.uk/site/literature/NASTOR/ and www.celsis.com/about-our-company/news-room/financial-news/2009/.Β 

Β 

Copies of the Offer Document and Form of Acceptance will be available from the offices of Capita Registrars, Corporate Actions, The Registry,Β 34 Beckenham Road,Β Beckenham,Β KentΒ BR3 4TU. The Offer Document may also be obtained from the website of Celsis, www. celsis.com/about-our-company/news-room/financial-news/2009/.

PRESS ENQUIRIES

For further information contact:Β 

Enquiries:

Celsis International plc

Tel: 01223 598 428

Jay LeCoque

Robyn LaLonde

Nomura Code Securities

Tel: 020 7776 1200

Chris Collins

Phil Walker

Financial Dynamics

Tel: 020 7831 3113

Jonathan Birt

Susan Quigley

This announcement does not constitute, or form part of, any offer for, or any solicitation of any offer for, securities. Any response to the Offer should be made only on the basis of information referred to in the Offer Document which Nastor Investments sent to Celsis Shareholders and, for information only, to holders of options under the Celsis Share Schemes on 10 August 2009.

The availability of the Offer to persons who are not resident in theΒ United KingdomΒ may be affected by the laws of the relevant jurisdiction in which they are located. Such persons should inform themselves of, and observe, any applicable legal or regulatory requirements of their jurisdiction. Any failure to comply with these requirements may constitute a violation of the securities laws at any such jurisdiction. Further details in relation to overseas shareholders are contained in the Offer Document.

The Offer referred to in this announcement is not being made available directly or indirectly, in, into or by use of the mails of, or by any means or instrumentality (including, without limitation, telephonically or electronically) or interstate or foreign commerce of, or any facilities of a nationals securities exchange of, the United States, Canada, Australia or Japan or any other jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction. This announcement does not constitute an offer in the United States, Canada, Australia or Japan or any such other jurisdiction and the Offer is being made available by any such use, means, instrumentality or facilities or otherwise from or within the United States, Canada, Australia or Japan or any such other jurisdiction. Accordingly this announcement is not being, and should not be, mailed, transmitted or otherwise distributed, in whole or in part, in or into or from the United States, Canada, Australia or Japan or any such other jurisdiction.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCSSSFIUSUSEEU
Date   Source Headline
8th Aug 20257:00 amRNSCancellation - Celadon Pharmaceuticals Plc
5th Aug 20256:00 pmRNSCeladon Pharmaceuticals
28th Jul 20254:10 pmRNSResult of General Meeting
2nd Jul 20257:00 amRNSProposed Cancellation
1st Jul 202511:48 amRNSFunding Update
1st Jul 20258:20 amRNSResult of AGM
1st Jul 20257:30 amRNSSuspension - Celadon Pharmaceuticals Plc
30th Jun 20257:00 amRNSFunding and Operational Update, Delay in Results
11th Jun 20257:00 amRNSNew Committed Credit Facility
6th Jun 20253:55 pmRNSFunding Update, Notice of AGM
30th May 20256:07 pmRNSFunding Update
30th Apr 20257:00 amRNSFunding Update
8th Apr 20253:05 pmRNSTermination of Facility
31st Mar 20253:15 pmRNSFunding Update
24th Mar 20257:00 amRNSBoard Changes and De-Listing Proposal
19th Mar 20257:00 amRNSFunding Update
26th Feb 20251:00 pmRNSNew Committed Credit Facility
12th Feb 20257:00 amRNSFinance Update
31st Jan 20257:00 amRNSFinance Update
16th Jan 20257:00 amRNSUpdate on Strategic Collaboration
2nd Jan 20257:00 amRNSFunding Update
20th Dec 20247:00 amRNSFinance Update
6th Dec 20247:00 amRNSReceipt of Subscription Proceeds
18th Nov 20247:00 amRNSUpdate on Financial Position
2nd Oct 20247:00 amRNSNew Sales Contract with a Healthcare Company
30th Sep 20247:05 amRNSDeparture of Chief Financial Officer
30th Sep 20247:00 amRNSInterim Results
17th Sep 20249:28 amRNSAdmission of Shares and Total Voting Rights
11th Sep 20247:05 amRNSEquity Fundraise and Update on Financial Position
11th Sep 20247:00 amRNSStrategic collaboration with Valeos
23rd Aug 20247:00 amRNSUpdate on Financial Position
12th Aug 20247:00 amRNSUpdate on Operations and Financial Position
16th Jul 20247:00 amRNSSuccessful Completion of Eighth Harvest of 2024
15th Jul 20241:58 pmRNSThird Admission of Shares
28th Jun 20247:00 amRNSResult of AGM
7th Jun 20247:00 amRNSSecond Admission of Shares
3rd Jun 20245:45 pmRNSPublication of Annual Report & Notice of AGM
23rd May 20247:00 amRNSSupply of Products to New US Customer
15th May 20242:45 pmRNSExercise of Share Options and Total Voting Rights
14th May 20247:00 amRNSFinal Results
10th May 20247:00 amRNSFundraise, RCF Extension, Termination of CLN & TVR
7th Mar 20247:00 amRNSEarly Economic Analysis of Feasibility Study Data
14th Dec 20237:00 amRNSProduct Supplied to First Two Sales Contracts
12th Dec 20232:00 pmRNSFundraise, Update on Future CLN Financing & TVR
16th Nov 20237:00 amRNSNew European Sales Contract
13th Oct 20237:00 amRNSFundraise, CLN Issue, Joint Broker Appointed & TVR
28th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSNotice of Results and Investor Presentation
5th Sep 20237:00 amRNSNew Sales Contract with UK Pharmaceutical Company
1st Aug 20237:00 amRNSApproval to roll-out chronic pain clinical trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.